Free Trial

Nevro Q3 2024 Earnings Report

Nevro logo
$5.74 +0.01 (+0.09%)
As of 02/21/2025 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Nevro EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.81
Beat/Miss
Beat by +$0.40
One Year Ago EPS
-$0.65

Nevro Revenue Results

Actual Revenue
$96.60 million
Expected Revenue
$93.09 million
Beat/Miss
Beat by +$3.51 million
YoY Revenue Growth
-7.00%

Nevro Announcement Details

Quarter
Q3 2024
Time
After Market Closes

Nevro Earnings Headlines

Nevro (NYSE:NVRO) and Adynxx (OTCMKTS:ADYX) Critical Comparison
Globus Medical price target lowered to $93 from $95 at Wells Fargo
Important: case study on TGT
Please take a look at THIS case study on Target (TGT) You’ll see exactly how the tool works to trade long and short, even when the markets seem to be predicting the exact opposite. Now, this tool has been so accurate over recent months that I’m planning to send you 14 more real-world examples of winning trades that anyone using this tool could have captured. And it’s all building to Monday, February 24 @ 1pm ET when I’ll bring the tool to the public for the first time and show you how you can put it on your own charts!
Nevro (NYSE:NVRO) Now Covered by Analysts at StockNews.com
See More Nevro Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Nevro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nevro and other key companies, straight to your email.

About Nevro

Nevro (NYSE:NVRO), a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.

View Nevro Profile

More Earnings Resources from MarketBeat